Product
mFOLFIRINOX
11 clinical trials
1 abstract
13 indications
Indication
Pancreatic Ductal AdenocarcinomaIndication
Pancreatic CancerIndication
AdenocarcinomaIndication
Pancreatic DuctalIndication
Pancreatic adenocarcinomaIndication
Colorectal CancerIndication
Colorectal cancerIndication
PDACIndication
Gastrointestinal CancerIndication
High-risk Stage II Colorectal CancerIndication
Circulating Tumor DNA MethylationIndication
Colon CancerClinical trial
A Randomized Phase 2b/Phase 3 Study of the TGF-β2 Targeting Antisense Oligonucleotide OT-101 in Combination With mFOLFIRINOX Compared With mFOLFIRINOX Alone in Patients With Advanced and Unresectable or Metastatic Pancreatic CancerStatus: Not yet recruiting, Estimated PCD: 2026-06-01
Clinical trial
A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Patients With Resected Pancreatic Ductal AdenocarcinomaStatus: Recruiting, Estimated PCD: 2029-12-27
Clinical trial
A Phase I/Randomized Phase II, Open-label Multicenter Trial to Evaluate the Safety, Tolerability, and Efficacy of mFOLFIRINOX With or Without BNT321 as Adjuvant Therapy Following Curative Resection in Patients With Pancreatic AdenocarcinomaStatus: Recruiting, Estimated PCD: 2029-04-01
Clinical trial
A Randomized Controlled Study of Suizenji in Patients With Unresectable Pancreatic CancerStatus: Recruiting, Estimated PCD: 2025-10-31
Clinical trial
Phase 1 Safety and Tolerability Study of Human Monoclonal Antibody 5B1 (MVT-5873) With Expansion in Subjects With Pancreatic Cancer or Other CA19-9 Positive MalignanciesStatus: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic CancerStatus: Recruiting, Estimated PCD: 2025-10-31
Clinical trial
A Platform Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid TumorsStatus: Recruiting, Estimated PCD: 2027-05-15
Clinical trial
PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration SamplesStatus: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
Circulating Tumor DNA Methylation Guided Postoperative Adjuvant Chemotherapy for High-risk Stage II/III Colorectal Cancer: A Multicenter, Prospective, Randomized Controlled Cohort Study (FINE Trial)Status: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
Preoperative Treatment With mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose Stereotactic Body Radiation Therapy (iHD-SBRT) for Borderline Resectable Pancreatic Adenocarcinoma: a Randomised Phase II Study (STEREOPAC)Status: Recruiting, Estimated PCD: 2027-12-31
Clinical trial
A Randomized Controlled Phase III Trial of Treatment Intensification in Stage II-III Colon Cancer Patients With Positive MRD During Adjuvant ChemotherapyStatus: Recruiting, Estimated PCD: 2028-09-30